SCIB1 Phase I Clinical Trial Commences

15 June 2010

                             Scancell Holdings Plc                             

                                 ('Scancell')                                  

                         SCIB1 Phase I Trial Commences                         

                             First Patient Treated                             

Scancell Holdings Plc, (PLUS:SCLP), the developer of therapeutic cancer
vaccines, today announces the enrolment and treatment of the first patient in
its multicentre Phase I clinical trial of SCIB1, its DNA ImmunoBody® vaccine
being developed for the treatment of melanoma. The trial will evaluate the
safety and tolerability of SCIB1 in patients with late stage melanoma.

The trial, which is commencing on schedule, will be in nine, Stage IV or
inoperable Stage III patients and is being conducted in three UK centres. All
patients in the clinical trial will be treated with Scancell's SCIB1 ImmunoBody
® vaccine, delivered by Ichor Medical Systems' TriGrid™ electroporation
delivery device.

ImmunoBody® vaccines generate the high-avidity T-cells* that kill cancer cells,
which may overcome the current limitations of most cancer vaccines. In vivo
electroporation is widely regarded as an effective method of enhancing the
potency of DNA vaccines by up to 100-fold compared to conventional methods of
delivery.

Advanced melanoma currently has a very poor prognosis with late stage (stage
IV) disease having a median survival of approximately six months. According to
the World Health Organisation, 132,000 melanoma skin cancers occur globally
each year and the incidence is increasing, especially in the United States,
Europe and Australia.

Professor Lindy Durrant, CEO of Scancell Holdings and Professor of Cancer
Immunotherapy at Nottingham University, commented: "This is the first time we
will be taking the SCIB1 ImmunoBody® vaccine into patients with late stage
melanoma and follows our very positive research studies with the vaccine
against this deadly form of cancer. We are very excited about the prospects for
SCIB1 and are very pleased that it has moved a step closer to becoming
available for the treatment of cancer patients."

Professor Poulam Patel, Lead Researcher, commented: "Advanced melanoma is one
of the most deadly cancers we have and there is an urgent need for new
treatments.  The data from the laboratories looks very promising and we're very
excited to take SCIB1 into the clinic." 

David Evans, Chairman of Scancell Holdings, commented: "The beginning of
enrolment in the Phase I trial for SCIB1 is a key milestone for Scancell and we
are delighted that the Company is continuing in its progress."

The Directors of the issuer accept responsibility for this announcement.


*High avidity T-cells - A type of white blood cell composed of CTL and Helper
cells. CTL cells recognise and kill tumour or virally infected cells, Helper
cells recognise and secrete molecules to alert the immune system to the
presence of a tumour or virally infected cell. Avidity measures the strength of
the T-cell interaction.

                                    -ENDS-                                     

For Further Information:

Professor Lindy Durrant, CEO Scancell Holdings Plc   + 44 207 245 1100 
                                                                     
Kirsty Corcoran/John Bick    Hansard Communications  + 44 207 245 1100 
                                                                                                                
Ross Andrews / Tom Rowley    Zeus Capital            + 44 161 831 1512 


About Scancell

Scancell is developing novel therapeutic vaccines for the treatment of cancer
and infectious diseases based on its groundbreaking ImmunoBody® technology
platform. Scancell's first cancer vaccine SCIB1 is being developed for the
treatment of melanoma and is expected to enter clinical trials in 2010.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be
administered to a patient, stimulating an immune response. Effective cancer
vaccines need to target dendritic cells to stimulate both parts of the cellular
immune system; the helper cell system where inflammation is stimulated at the
tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system
cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they
cannot specifically target dendritic cells in vivo. Several groups have
demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing
them with tumour antigens and re-infusing them. However, this procedure is
patient specific, time consuming and expensive. Scancell has developed its
breakthrough patent protected ImmunoBody® technology to overcome these
limitations.

An ImmunoBody® is a human antibody or fusion protein engineered to express
helper cell and CTL epitopes from tumour antigens over-expressed by cancer
cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour
antigens as they have long half-lives and can effectively target dendritic
cells via their Fc receptors, allowing efficient stimulation of both helper and
CTL responses.

The Immunobody® technology can be adapted to provide the basis for treating any
tumour type and may also be of potential utility in the development of vaccines
against hepatitis, HIV and other chronic infectious diseases.